These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 1308914)

  • 1. [Bone mineral content and treatment with deferoxamine in patients under chronic hemodialysis].
    Zanchetta JR; Bogado CE; Zuchini A; Firmat J
    Medicina (B Aires); 1992; 52(2):184-5. PubMed ID: 1308914
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease.
    Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; van Hooff I; Dratwa M; Verbeelen D
    Clin Nephrol; 1985 Nov; 24(5):237-41. PubMed ID: 4075595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Osteomalacia induced by aluminum in a patient under chronic hemodialysis: successful treatment with desferrioxamine].
    Espinoza O; Gehrung E; Roessler E; Katz E; Pérez A; Delmastro J
    Rev Med Chil; 1986 Sep; 114(9):867-71. PubMed ID: 3575972
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 5. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 6. Aluminum-related osteomalacia: clinical and histological improvement following treatment with desferrioxamine (DFO).
    Rapoport J; Chaimovitz C; Abulfil A; Mostovlavsky M; Gazit D; Bab I
    Isr J Med Sci; 1987 Dec; 23(12):1242-6. PubMed ID: 3440748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine.
    Mudde AH; Roodvoets AP; Van Groningen K
    Neth J Med; 1985; 28(1):6-11. PubMed ID: 3974771
    [No Abstract]   [Full Text] [Related]  

  • 8. Aluminum bone disease. (A case study).
    Coleman S
    J Nephrol Nurs; 1985; 2(3):125-6. PubMed ID: 3848476
    [No Abstract]   [Full Text] [Related]  

  • 9. [Aluminum-induced osteomalacia in chronic hemodialysis].
    Smetana S; Popovtzer MM; Bar-Khayim Y
    Harefuah; 1987 Jun; 112(12):595-7. PubMed ID: 3428727
    [No Abstract]   [Full Text] [Related]  

  • 10. [The deferoxamine loading test as a non-invasive method for diagnosing Al-related bone disease in hemodialysis patients; efficacy of deferoxamine therapy for the disease].
    Umetani N; Sato N; Yoshida A; Marumo F
    Nihon Jinzo Gakkai Shi; 1988 Feb; 30(2):143-50. PubMed ID: 3386018
    [No Abstract]   [Full Text] [Related]  

  • 11. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desferrioxamine and osteomalacia.
    Mudde AH; Roodvoets AP
    Lancet; 1982 Sep; 2(8298):608. PubMed ID: 6125750
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical and biochemical features of aluminum-related bone disease.
    Ihle BU; Becker GJ; Kincaid-Smith PS
    Kidney Int Suppl; 1986 Feb; 18():S80-6. PubMed ID: 3458003
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report 294. Diagnosis: dialysis osteomalacia with response to desferrioxamine therapy.
    Xipell JM; Ham KN; Brown DJ; Dawborn JK
    Skeletal Radiol; 1984; 12(4):298-302. PubMed ID: 6505735
    [No Abstract]   [Full Text] [Related]  

  • 17. Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis.
    Faugere MC; Arnala IO; Ritz E; Malluche HH
    J Lab Clin Med; 1986 Jun; 107(6):481-7. PubMed ID: 3486929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined hemofiltration and desferrioxamine treatment for aluminum induced osteomalacia.
    Barré PE; Prichard S
    Int J Artif Organs; 1986 May; 9(3):167-72. PubMed ID: 3733242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH; Faugere MC; Smith AJ; Friedler RM
    Kidney Int Suppl; 1986 Feb; 18():S70-3. PubMed ID: 3458000
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P; Ralston AJ; Day JP
    Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.